• 1
    Elias L. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP). Cancer. 1978; 42: 17051710.
  • 2
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985; 102: 596602.
  • 3
    Fisher RI. Diffuse aggressive lymphomas: increased survival after alternating flexible sequence of PROMACE and MOPP chemotherapy. Ann Intern Med. 1983; 98: 304309.
  • 4
    Fisher RI, DeVita VTJ, Hubbard SM. Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol. 1984; 3: 242.
  • 5
    Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986; 104: 757765.
  • 6
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 7
    Gordon LI, Harrington DP, Andersen J, et al. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992; 327: 13421349.
  • 8
    Sertoli MR, Satini G. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trail by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1994; 12: 13661374.
  • 9
    Cooper IA, Wolff MM, Robertson TI. Randomized comparison of CHOP in patients with intermediate-grade non-Hodgkin's lymphoma.The Australian and New Zealand Lymphoma Group. J Clin Oncol. 1994; 12: 769778.
  • 10
    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19: 389397.
  • 11
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 28252833.
  • 12
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood. 1998; 92: 19271932.
  • 13
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 14
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23: 41174126.
  • 15
    Habermann TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 102: 6a. Abstract 8.
  • 16
    Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood. 2004; 104: 40a. Abstract 127.
  • 17
    Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 556a. Abstract 6500.
  • 18
    Pfreundschuh MG, Trumper, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379391.
  • 19
    Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23: 50275033.
  • 20
    Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003; 9: 3982S3990S.
  • 21
    Cesano A, Gayko U, Brannan C, et al. Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted immunotherapy [abstract]. Blood. 2002; 100: 350a. Abstract 1358.
  • 22
    Stein R, Qu Z, Chen S, et al. Mechanisms of anti-lymphoma effects of the humanized anti-CD22 monoclonal antibody, epratuzumab and combination studies with anti-CD20 MAbs [abstract]. Blood. 2003; 102: 298b. Abstract 4917.
  • 23
    Gada P, Hernandez-Ilizaliturri FJ, Repasky EA, et al. Epratuzumab's predominant antitumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibody-dependent cellular cytotoxicity (ADCC) [abstract]. Blood. 2002; 100: 353a. Abstract 1367.
  • 24
    Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 30513059.
  • 25
    Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti CD-22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res. 2004; 10: 53275334.
  • 26
    Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 50445051.
  • 27
    Strauss SJ, Lister A, Morschauser F, et al. Multi-centre, Phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: promising preliminary results [abstract]. Proc Am Soc Clin Oncol. 2004; 22: 577s.
  • 28
    Strauss SJ, Morschhauser F, Rech J, et al. Multicenter Phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24: 38803886.
  • 29
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 30
    Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive NHL: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987994.
  • 31
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol. 1999; 17: 12441253.
  • 32
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 33
    Pfreundschuh MG, Ho A, Wolf M, et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study. J Clin Oncol. 2005; 23( suppl): 567s. Abstract 6529.
  • 34
    Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts). 2005; 106: 9a. Abstract 13.
  • 35
    Morrison VA, Weller EA, Habermann TM, et al. Patterns of growth factor (GF) usage and febrile neutropenia (FN) among older patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). Blood. 2004; 104: 904a. Abstract 3309.
  • 36
    McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma. 2006; 47: 965966.
  • 37
    Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006; 47: 10131017.